Venlafaxine Hydrochloride Capsule, Extended Release
Product Images NDC 70518-4154

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Venlafaxine Hydrochloride (NDC 70518-4154). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Remedy_label (Remedy Label)

The packaging label for Venlafaxine Extended-Release 150 mg capsules by RemedyRepack Inc. shows a quantity of 30 capsules. It includes the NDC number 70518-4154-00, manufacturer Epic Pharma, LLC in Laurelton, NY, and storage instructions at 20-25°C with permitted excursions. The label advises keeping the medication out of children's reach and refers to the package insert for directions.*

FDA Label Image

Image-01 (Image 01)

Chemical structure of venlafaxine hydrochloride, showing the molecular configuration with aromatic ring, cyclohexane ring, and dimethylamino group as part of the compound's framework.*

FDA Label Image

Image-02 (Image 02)

A dot plot chart that shows fold change and 90% confidence intervals of pharmacokinetic parameters (Cmax and AUC) of venlafaxine and its metabolite ODV in various special populations. The populations include different levels of hepatic impairment, renal impairment, CYP2D6 metabolizer status, age over 60 years, and gender. The x-axis represents change relative to the reference value from 0 to 3.5, with a reference line at 1.0.*

FDA Label Image

Image-03 (Image 03)

A forest plot showing the fold change and 90% confidence intervals for venlafaxine pharmacokinetic (PK) parameters, including Cmax and AUC of venlafaxine and its metabolite ODV, when co-administered with various interacting drugs such as ethanol, diazepam, cimetidine, ketoconazole, indinavir, metoprolol, imipramine, and lithium. The x-axis represents change relative to the reference value.*

FDA Label Image

Image-04 (Image 04)

A scatter plot chart showing the fold change and 90% confidence intervals in pharmacokinetic parameters (Cmax and AUC) for various analytes when interacting with different drugs. The chart displays changes relative to a reference value of 1, with drugs listed including ethanol, diazepam, alprazolam, indinavir, metoprolol, risperidone, imipramine, haloperidol, caffeine, tolbutamide, and lithium.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.